Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H16FN3O2S.C4H4O4 |
Molecular Weight | 461.463 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.CNCC1=CN(C(=C1)C2=C(F)C=CC=C2)S(=O)(=O)C3=CC=CN=C3
InChI
InChIKey=ROGSHYHKHPCCJW-WLHGVMLRSA-N
InChI=1S/C17H16FN3O2S.C4H4O4/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14;5-3(6)1-2-4(7)8/h2-9,11-12,19H,10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Molecular Formula | C17H16FN3O2S |
Molecular Weight | 345.391 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.takeda.com/news/2015/20150226_6922.htmlCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25744862|
https://www.ncbi.nlm.nih.gov/pubmed/20624992
Sources: https://www.takeda.com/news/2015/20150226_6922.html
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25744862|
https://www.ncbi.nlm.nih.gov/pubmed/20624992
Vonoprazan (Vonoprazan fumarate or TAK-438) under brand name Takecab, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits the binding of potassium ions to H+,K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. The drug is approved in Japan for the treatment of acid-related diseases, including gastric ulcer, duodenal ulcer, reflux esophagitis and Adjunct to Helicobacter pylori eradication in the case of Helicobacter pylori gastritis.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25744862
Curator's Comment: # Takeda
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095173 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20624992 |
0.003 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TAKECAB Approved UseUnknown |
|||
Curative | TAKECAB Approved UseUnknown |
|||
Curative | TAKECAB Approved UseUnknown |
|||
Primary | TAKECAB Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26369775
Orally at 20 mg once daily for the treatment of gastroduodenal ulcer, at 20 and 10 mg once daily for the treatment and secondary prevention of reflux esophagitis, respectively, at 10 mg once daily for the secondary prevention of low-dose aspirin- or non-steroidal anti-inflammatory drug-induced peptic ulcer, and at 20 mg twice daily in combination with clarithromycin and amoxicillin for the eradication of Helicobacter pylori.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20624992
TAK-438 (Vonoprazan) inhibited H(+),K(+)-ATPase activity in porcine gastric microsomes with IC(50) values of 0.019 μM at pH 6.5. The inhibitory activity of TAK-438 was unaffected by ambient pH. The inhibition by TAK-438 was reversible and achieved in a K(+)-competitive manner.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 01:55:11 GMT 2023
by
admin
on
Sat Dec 16 01:55:11 GMT 2023
|
Record UNII |
4QW3X4AMLB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2604576
Created by
admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
|
PRIMARY | |||
|
SUB181653
Created by
admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
|
PRIMARY | |||
|
4QW3X4AMLB
Created by
admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
|
PRIMARY | |||
|
4QW3X4AMLB
Created by
admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
|
PRIMARY | |||
|
SUB88193
Created by
admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
|
PRIMARY | |||
|
1260141-27-2
Created by
admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
100000139518
Created by
admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
|
PRIMARY | |||
|
881681-01-2
Created by
admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
|
PRIMARY | |||
|
45375887
Created by
admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
|
PRIMARY | |||
|
m11860
Created by
admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
|
PRIMARY | |||
|
C151949
Created by
admin on Sat Dec 16 01:55:11 GMT 2023 , Edited by admin on Sat Dec 16 01:55:11 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|